A multidisciplinary team approach to care is fostered through peer-to-peer discussion and collaboration. The team diagnosis and treatment, includes radiological, pathological findings and immunohistochemical testing, bridges these gaps across the continuum of care in order to enhance the overall quality of patient-centered breast cancer care.
Medical Oncologists, Radiation Oncologists, Breast Cancer Surgeons, General Surgeons, Pathologists, Radiologists, Gynecologists, Nurses, Patient Care Facilitators and all personnel involved in the care of the breast cancer patient.
- Implement optimal course of treatment for breast cancer patients.
- Utilize multiple disciplinary approaches to diagnosis and treatment options, including radiological findings, pathological findings and immunohistochemical testing.
- Determine cancer staging using various breast imaging modalities.
- Promote a multidisciplinary team approach by bridging gaps across the continuum of care in order to enhance the overall quality of patient-centered breast cancer care.
MODERATOR: Raul Arroyo, M.D.
Core Group of Contributors:
Surgeons: L. Raúl Arroyo, M.D., FACS, Andrew H. Rosenthal, M.D.
Radiologists: Carol A. Adami, M.D., Ariana Alvarez, M.D., Darlene Da Costa, M.D.
Pathologist: Kenneth Bengtson, M.D.
Rad/Oncologists: Alicia Gittleman, M.D., Claude Harmon, M.D., James Parsons, M.D.
Med/Oncologists: Mindy Bohrer, M.D., Felix Rodriguez-Pinero, M.D.
Genetics: Jessica McAfee, MSN, APRN, FNP-BC,
Dawn Blackshear, MSN, APRN, FNP-BC
Nurse Navigator: Michele Goldberg, BSN, RN
In accordance with the Standards of Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME), which requires balance, independence, objectivity and scientific rigor in all CME programming, Baptist Health has identified and resolved conflicts of interest of all individuals that control CME content, including faculty, planners and members of the Continuing Medical Education Committee and the Continuing Medical Education Department. Dr. Carol Adami has indicated that she, is on the speakers’s bureau for Myriad Genetics. All other contributors and all core group members have indicated that they have no significant financial relationship with commercial interest to disclose. Dr. Adami has indicated that her discussion will not include mention of investigational or off-label usage. In addition, all other moderators do not anticipate comments will include discussion of unapproved off-label use of any products. Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.